Canaccord analyst Whitney Ijem initiated coverage of Pharming (PHAR) with a Buy rating and $37 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAR:
- Pharming Group Files 2025 Annual Report and Form 20-F
- Pharming Group Wins Positive EMA Panel Backing for Joenja in Rare APDS
- Pharming announces approval of Joenja in Japan for patients aged 4 years and old
- Pharming Group Wins Landmark Japan Approval for Joenja in Pediatric and Adult APDS
- Pharming price target lowered to $41 from $42 at Oppenheimer